AbbVie shells out $440M on two PRVs for label expansions of its blockbuster Rinvoq
The priority review voucher market can be notoriously secretive, especially when companies purchase PRVs and don’t disclose where they’re planning to use the expedited FDA …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
